<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04378543</url>
  </required_header>
  <id_info>
    <org_study_id>ART-SPF-ART352L-001</org_study_id>
    <nct_id>NCT04378543</nct_id>
  </id_info>
  <brief_title>Safety Evaluation of ART352-L in Subjects Undergoing Posterolateral Spinal Fusion</brief_title>
  <official_title>A Phase 1b/2a Safety Evaluation of ART352-L in Subjects Undergoing Posterolateral Spinal Fusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ankasa Regenerative Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ankasa Regenerative Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ankasa Regenerative Therapeutics, Inc. (Ankasa) is developing ART352-L, a liposomal&#xD;
      formulation of recombinant human Wnt3A protein, that is applied ex vivo, to harvested&#xD;
      autologous bone grafts (autograft) to enhance the osteogenic properties of the autograft&#xD;
      prior to reimplantation in orthopedic surgeries.&#xD;
&#xD;
      This is a phase 1/2 open label safety evaluation of ART352-L treated autologous bone grafts&#xD;
      in patients undergoing posterolateral lumbar spinal fusion to treat single level degenerative&#xD;
      spondylolisthesis. The primary objective of the study is to evaluate the safety and&#xD;
      tolerability of ART352-L treated local bone autografts in patients being treated for this&#xD;
      condition, with the secondary objective to evaluate the rates of early and overall spinal&#xD;
      fusion. Additionally, changes in patient mobility and quality of life measures from baseline&#xD;
      following treatment with ART352-L will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2020</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>2 weeks</time_frame>
    <description>Incidence of adverse events and adverse events of special interest</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>8 weeks</time_frame>
    <description>Incidence of adverse events and adverse events of special interest</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>26 weeks</time_frame>
    <description>Incidence of adverse events and adverse events of special interest</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>52 weeks</time_frame>
    <description>Incidence of adverse events and adverse events of special interest</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>104 weeks</time_frame>
    <description>Incidence of adverse events and adverse events of special interest</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of early fusion</measure>
    <time_frame>26 weeks</time_frame>
    <description>Rate of early fusion using Lenke scoring of computed tomography (CT) scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of fusion</measure>
    <time_frame>52 weeks</time_frame>
    <description>Rate of fusion using Lenke scoring of CT scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of fusion</measure>
    <time_frame>104 weeks</time_frame>
    <description>Rate of fusion using Lenke scoring of CT scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oswestry Disability Index</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change from baseline in Oswestry Disability Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oswestry Disability Index</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change from baseline in Oswestry Disability Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oswestry Disability Index</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in Oswestry Disability Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oswestry Disability Index</measure>
    <time_frame>104 weeks</time_frame>
    <description>Change from baseline in Oswestry Disability Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form-36 (SF-36)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change from baseline in Short Form-36 (SF-36) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form-36 (SF-36)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change from baseline in Short Form-36 (SF-36) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form-36 (SF-36)</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in Short Form-36 (SF-36) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form-36 (SF-36)</measure>
    <time_frame>104 weeks</time_frame>
    <description>Change from baseline in Short Form-36 (SF-36) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) Pain</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change from baseline in Visual Analog Scale (VAS) Pain assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) Pain</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change from baseline in Visual Analog Scale (VAS) Pain assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) Pain</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in Visual Analog Scale (VAS) Pain assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Scale (VAS) Pain</measure>
    <time_frame>104 weeks</time_frame>
    <description>Change from baseline in Visual Analog Scale (VAS) Pain assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes Measurement Information System (PROMIS) - Global 10</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change from baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Global-10 Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes Measurement Information System (PROMIS) - Global 10</measure>
    <time_frame>26 weeks</time_frame>
    <description>Change from baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Global-10 Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes Measurement Information System (PROMIS) - Global 10</measure>
    <time_frame>52 weeks</time_frame>
    <description>Change from baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Global-10 Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes Measurement Information System (PROMIS) - Global 10</measure>
    <time_frame>104 weeks</time_frame>
    <description>Change from baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Global-10 Score</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Degenerative Spondylolisthesis</condition>
  <arm_group>
    <arm_group_label>ART252-L</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>local autologous bone graft will be treated ex vivo once with ART352-L prior to re-implantation into the site of spinal fusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ART352-L</intervention_name>
    <description>recombinant human Wnt3a protein delivered on liposomes to local autologous bone graft during posterolateral fusion procedures</description>
    <arm_group_label>ART252-L</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects ≥50 years of age scheduled to undergo single level&#xD;
             posterolateral lumbar spinal fusion surgery in conjunction with local autograft bone&#xD;
             for degenerative spondylolisthesis&#xD;
&#xD;
          2. Psychosocially, mentally, and physically able to fully comply with this protocol&#xD;
             including the required follow-up visits, the filling out of required forms, and have&#xD;
             the ability to understand and give written informed consent&#xD;
&#xD;
          3. Willing and able to undergo diagnostic imaging, inclusive of X-rays and CT scans with&#xD;
             contrast&#xD;
&#xD;
          4. Persistent, disabling pain after at least 6 months of non-surgical intervention (e.g.,&#xD;
             anti-inflammatory medication, physical therapy, chiropractic care) prior to providing&#xD;
             informed consent&#xD;
&#xD;
          5. Pre-operative Oswestry Disability Index (ODI) Score ≥30&#xD;
&#xD;
          6. Grade 1 or less spondylolisthesis or retrolisthesis&#xD;
&#xD;
          7. Absence of neurological motor deficit&#xD;
&#xD;
          8. Agree to use a highly reliable method of birth control (male and female subjects) for&#xD;
             at least 90 days after administration of Investigational Product (IP) - Women of&#xD;
             childbearing potential must have a negative pregnancy test at screening and again ≤7&#xD;
             days prior to surgery. Perimenopausal women must be amenorrheic for at least 12 months&#xD;
             prior to the time of providing informed consent to be considered of non-childbearing&#xD;
             potential.&#xD;
&#xD;
          9. Agree to remain nicotine-free for the duration of their participation in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Multiple level spondylolistheses or a primary diagnosis of low back pain syndrome&#xD;
             secondary to diseases other than degenerative spondylolisthesis&#xD;
&#xD;
          2. Concurrent medications that affect bone homeostasis including, but not limited to,&#xD;
             bisphosphonates&#xD;
&#xD;
          3. Ongoing / existing infections in or around the surgical site or spine&#xD;
&#xD;
          4. Prior lumbar spine arthrodesis&#xD;
&#xD;
          5. Concurrent clinically significant autoimmune disorder or systemic inflammatory disease&#xD;
&#xD;
          6. Known hypersensitivity to recombinant Wnt proteins&#xD;
&#xD;
          7. Use of tobacco; subjects must be nicotine-free at screening and agree to remain&#xD;
             nicotine free for the duration of the study&#xD;
&#xD;
          8. Use of medications that may impair cell proliferation and bone healing including:&#xD;
             chemotherapy, radiation, chronic steroids and immunosuppressive drugs. Note:&#xD;
             Medications that may impair cell proliferation are to be discussed with the protocol&#xD;
             medical monitor prior to enrollment&#xD;
&#xD;
          9. Severe established osteoporosis requiring active treatment e.g., with bone density&#xD;
             more than 2.5 standard deviations below the young adult mean with one or more&#xD;
             osteoporotic fractures&#xD;
&#xD;
         10. A Body Mass index (BMI) ≥ 40 unless documentation clearly demonstrates why BMI is not&#xD;
             a primary factor in the subject's decreased mobility&#xD;
&#xD;
         11. Chronic opioid use&#xD;
&#xD;
         12. History of deep vein thrombosis (DVT) or blood clotting abnormalities&#xD;
&#xD;
         13. Uncontrolled diabetes mellitus&#xD;
&#xD;
         14. Pre-operative/anesthesia evaluations deeming the subject ineligible for surgery&#xD;
&#xD;
         15. Female subjects who are pregnant or intend to become pregnant during the course of the&#xD;
             study&#xD;
&#xD;
         16. Male subjects, if not infertile or surgically sterilized, who will not agree to use&#xD;
             highly-effective contraception or to not donate sperm from screening until at least 90&#xD;
             days after receiving IP&#xD;
&#xD;
         17. Active malignancy ≤5 years prior to providing informed consent. EXCEPTIONS:&#xD;
             Non-melanotic skin cancer, carcinoma-in-situ of the cervix. NOTE: If there is a&#xD;
             history of prior malignancy, the subject must not be receiving other specific&#xD;
             treatment for their cancer.&#xD;
&#xD;
         18. Concurrent participation in another investigational drug, biologic or device study&#xD;
             that could confound study data&#xD;
&#xD;
         19. Involvement in or plans to engage in litigation or receiving Worker's Compensation&#xD;
             related to neck, back, or leg pain&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gloria Matthews, DVM, PhD</last_name>
    <phone>404-947-6472</phone>
    <email>gmatthews@wnt3.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sanford Madigan, PhD</last_name>
    <email>smadigan@wnt3.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Keck School of Medicine, University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Wang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brett Freedman, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wexner Medical Center, The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Safdar Khan, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 30, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2020</study_first_posted>
  <last_update_submitted>October 9, 2020</last_update_submitted>
  <last_update_submitted_qc>October 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spine</keyword>
  <keyword>spondylolisthesis</keyword>
  <keyword>degenerative disc disease</keyword>
  <keyword>back pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylolisthesis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

